Condition (MeSH)
Anemia, Hemolytic, Congenital Nonspherocytic
ClinicalTrials.gov lists 3 trials for Anemia, Hemolytic, Congenital Nonspherocytic or a narrower condition beneath it. Agios Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
4 sections measured, none recorded · 1 not measured yet · 1 not computed
3 of the 3 trials are tagged with Anemia, Hemolytic, Congenital Nonspherocytic itself; the rest are tagged with a narrower condition beneath it.
When did Anemia, Hemolytic, Congenital Nonspherocytic trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2021 | 2 |
| 2018 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Anemia, Hemolytic, Congenital Nonspherocytic trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Observational | 3 |
How many Anemia, Hemolytic, Congenital Nonspherocytic trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 1 |
| Completed | 1 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Anemia, Hemolytic, Congenital Nonspherocytic trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Agios Pharmaceuticals, Inc. | 3 |
Which publications cover Anemia, Hemolytic, Congenital Nonspherocytic? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency. | Blood advances | 2024 | Yes |
| Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency. | American journal of hematology | 2023 | Yes |
| The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design. | BMJ open | 2023 | Yes |
| Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. | Blood advances | 2022 | Yes |
| Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. | American journal of hematology | 2020 | Yes |
Showing 5 of 11 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.